EVMN - NOTRELOAD AI

Featured/ EVMN/ 06/29/2026 · 10:04 AM

Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued

Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.

Featured/ APGE/ 06/22/2026 · 5:39 AM

AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition

The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.

Evommune’s IL-18 Inhibitor Shows Significant Efficacy in Atopic Dermatitis Patients

EVMN/ 02/10/2026 · 9:13 AM

EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis

Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.

EVMN/ 01/08/2026 · 11:56 AM

Raymond James Starts Coverage on Evommune with Strong Buy Rating

Raymond James begins coverage of Evommune with a Strong Buy rating and a $40 price target, highlighting key Phase 2 clinical catalysts expected in 2026.

#EVMN↓

Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued

AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition

EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis

Raymond James Starts Coverage on Evommune with Strong Buy Rating